Biomimetic strategies for targeted nanoparticle delivery

Summary

This review analyzes biomimetic methods for directing nanoparticles to selected tissues or disease sites. Traditional targeted carriers commonly rely on purpose-built antibodies, aptamers, or other ligands, which require discovery and optimization before they can be attached to a particle. Biomimetic strategies instead borrow recognition interactions already used by cells, pathogens, or other biological systems. The authors categorize recent approaches and discuss how naturally evolved targeting functions can alter tissue localization and thereby improve drug-delivery or imaging performance. The principal argument is that using existing biological interactions may reduce some ligand-discovery burden and offer multicomponent functions that are difficult to design from first principles. This framework is significant because targeting remains a major determinant of whether a nanocarrier reaches useful concentrations at its intended site. The review does not claim that biomimicry guarantees delivery, and the abstract supplies no systematic evidence synthesis, quantitative comparisons, or clinical outcomes. It does not establish which strategy performs best, how source variability affects targeting, or whether natural interactions remain specific after material processing. Biodistribution, off-target uptake, immunogenicity, reproducibility, manufacturing, storage, and regulatory control are not resolved, so the work should guide design choices rather than be read as proof of clinical superiority.